Two viewpoint articles published in JAMA Oncology provide opposing opinions on the benefit of testing for programmed death-ligand 1 (PD-L1) expression in patients with non-small-cell lung cancer ...
Professional antigen-presenting cells—monocytes and macrophages—engulf these proteins, digest them into short peptide ...
Functional Characterization and a Real-World Clinical Laboratory Pilot of the Foundation for the National Institutes of Health Circulating Tumor DNA Quality Control Materials A total of 871 patient ...
Robert Kratzke, MD, urged insurance providers to prioritize fast biomarker testing in non–small cell lung cancer, saying it’s both cost-effective and life-saving. Delays in molecular testing for ...
Survival in Patients With Low Expression of Wild-Type Homologous Recombination Genes: Refining the Homologous Recombination Paradigm in Colorectal Cancer Among 556 patients with mNSCLC, 98.8% received ...
A PD-L1 score for head and neck cancer helps guide treatment decisions, including when immunotherapy may be used. Here’s what your results mean.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results